On April 18, 2023 at 09:30:01 ET an unusually large
$5.00K block of Put contracts in Blue Chip Value Fund
(BLU) was bought,
with a strike price of $12.50 / share, expiring in 3 day(s) (on April 21, 2023).
Fintel tracks all large options trades, and the premium spent on this trade was � sigmas above the mean, placing it in the th percentile of all recent large trades made in BLU options.
This trade was first picked up on Fintel’s real time Unusual Option Trades
tool, where unusual option trades are highlighted.
What is the Fund Sentiment?
There are 154 funds or institutions reporting positions in Blue Chip Value Fund.
This is an increase
of
2
owner(s) or 1.32% in the last quarter.
Average portfolio weight of all funds dedicated to BLU is 0.51%,
a decrease
of 24.57%.
Total shares owned by institutions increased
in the last three months by 0.51% to 115,585K shares.
The put/call ratio of BLU is 1.83, indicating a
bearish
outlook.
Analyst Price Forecast Suggests 87.71% Upside
As of April 6, 2023,
the average one-year price target for Blue Chip Value Fund is $13.63.
The forecasts range from a low of $3.76 to a high of $25.52.
The average price target represents an increase of 87.71% from its latest reported closing price of $7.26.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Blue Chip Value Fund
is $0MM.
The projected annual non-GAAP EPS
is -$0.64.
What are Other Shareholders Doing?
Royal Bank Of Canada
holds 201K shares
representing 0.16% ownership of the company.
In it’s prior filing, the firm reported owning 38K shares, representing
an increase
of 81.22%.
The firm
increased
its portfolio allocation in BLU by 277.67% over the last quarter.
Ensign Peak Advisors
holds 409K shares
representing 0.32% ownership of the company.
No change in the last quarter.
EAM Investors
holds 20K shares
representing 0.02% ownership of the company.
In it’s prior filing, the firm reported owning 98K shares, representing
a decrease
of 389.37%.
The firm
decreased
its portfolio allocation in BLU by 85.01% over the last quarter.
ProShare Advisors
holds 10K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 11K shares, representing
a decrease
of 1.72%.
The firm
decreased
its portfolio allocation in BLU by 30.13% over the last quarter.
Boxer Capital
holds 3,200K shares
representing 2.53% ownership of the company.
No change in the last quarter.
Bellus Health Background Information
(This description is provided by the company.)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
See all Blue Chip Value Fund regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
